



General Announcement

Initiated by ASIATIC DEVELOPMENT - COMMON on 07/07/2008
05:30:41 PM

Submitted

Ownership transfer to ASIATIC DEVELOPMENT/EDMS/KLSE on
07/07/2008 05:31:26 PM

Submitted by ASIATIC DEVELOPMENT on 07/07/2008 05:35:23 PM

Reference No AD-080707-43F98

Form Version V3.0

Company Information	
Main Board/ Second Board Company	
New Announcement	
Submitting Investment Bank/Advisor (if applicable)	
Submitting Secretarial Firm (if applicable)	
* Company name	ASIATIC DEVELOPMENT BERHAD
* Stock name	ASIATIC
* Stock code	2291
* Contact person	MS LOH BEE HONG
* Designation	COMPANY SECRETARY
* Contact number	03-23336120
E-mail address	elaine.loh@genting.com

Type * Announcement

Subject *: RECURRENT RELATED PARTY TRANSACTION OF A REVENUE OR TRADING NATURE FROM 1 JULY 2008 TO 31 DECEMBER 2008

Note: If the announcement is a long announcement, please summarize the announcement in the contents and enter the details of the announcement in the Announcement Details or attached the full details of the announcement as attachment.

Contents *:-

(This field is to be used for the summary of the announcement)

1. INTRODUCTION

The Board of Directors of Asiatic Development Berhad ("Asiatic") wishes to announce that Asiatic Centre for Genome Technology Sdn Bhd ("ACGT"), a wholly-owned subsidiary of Asiatic, will enter into a recurrent related party transaction of a revenue or trading nature, which is necessary for its day-to-day operations with SGSI-Asiatic Limited ("SGSI-Asiatic"), a related party of Asiatic ("Recurrent Transaction").

2. DETAILS OF THE RECURRENT TRANSACTION

ACGT is set up as a centre of excellence in genomic science that focuses on the application of genome technology for the improvement of oil palm and other crops.

ACGT in its ordinary course of business, enters into recurrent related party transactions of a revenue or trading nature, which are necessary for the day-to-day operations with certain related parties of the Asiatic Group. The Recurrent Transaction will be carried out on an arm's length basis and on commercial terms which are not more favourable to the related parties than those generally available to the public and which will not be detrimental to the minority shareholders of the Company. The Recurrent Transaction is disclosed in Table 1.

3. RATIONALE FOR THE RECURRENT TRANSACTION

SGSI-Asiatic Limited is an equally owned joint venture entity by ACGT and Synthetic Genomics Inc ("Synthetic Genomics").

SGSI-Asiatic is principally engaged in research and development activities to increase the yield and profit stream principally from oil palm and other crops with the use of genomics-based techniques and other methods or tools

The Recurrent Transaction is in line with Asiatic Group's long term strategy for sustaining profit in oil palm and agricultural business. ACGT would focus its research and development activities to develop and commercialise genomics-based solutions to produce improved planting materials that would increase yield and enhance value creation from oil palm and other crops. This would also contribute to the growth in the agriculture sector through innovations in biotechnology.

As stated under Section 2 above, the Recurrent Transaction will be carried out on an arm's length basis and on commercial terms which are not more favourable to the related parties than those generally available to the public and which will not be detrimental to the minority shareholders of the Company.

4. FINANCIAL EFFECTS OF THE RECURRENT TRANSACTION

The Recurrent Transaction will not have any effect on the issued and paid-up share capital and major shareholders' shareholdings of Asiatic, and is not expected to have a material effect on the net assets per share, earnings per share and gearing of the Asiatic Group.

5. DIRECTORS' AND MAJOR SHAREHOLDER'S INTERESTS

The interests of the Directors and major shareholders of Asiatic in the Recurrent Transaction are set out in Table 1. Save as disclosed in Table 1 and as far as the Directors are aware, none of the other Directors, major shareholders of Asiatic or persons connected to them has any interest, direct or indirect, in the Recurrent Transaction.

6. DIRECTORS' RECOMMENDATION

The Directors, excluding Tan Sri Lim Kok Thay who abstained due to his interest in the Recurrent Transaction, after due consideration of all aspects of the Recurrent Transaction, are of the opinion that the Recurrent Transaction are in the best interest of the Company.

7. COMPLIANCE WITH SECURITIES COMMISSION ("SC") GUIDELINES

The Recurrent Transaction is in compliance with and there has been no departure from the Guidelines on the Offering of Equity and Equity-Linked Securities by the SC.

8. APPROVALS REQUIRED

The Recurrent Transaction is not subject to any approvals including approval from shareholders of the Company.

TAN SRI MOHD AMIN BIN OSMAN
Chairman

Asiatic Development Berhad

Announcement Details :-

(This field is for the details of the announcement, if applicable)

Attachment(s):- (please attach the attachments here)

📎 [RPT Announcement.pdf](#)

Tables Section - This section is to be used to create and insert tables. Please make the appropriate reference to the table(s) in the Contents of the Announcement:

© 2008 Bursa Malaysia Berhad. All rights reserved.

Details of Recurrent Related Party Transactions

Table 1

Item No.	Asiatic Development Berhad ("ADB") and/or its subsidiaries	Transacting Party	Nature of Relationship	Nature of Transaction	Estimated Value from 1 July 2008 to 31 December 2008
1.	Asiatic Centre for Genome Technology Sdn Bhd ("ACGT")	SGSI-Asiatic Limited ("SGSI-Asiatic")	<p>Tan Sri Lim Kok Thay</p> <ul style="list-style-type: none"> -Director and shareholder of ADB -Director, shareholder and share option holder of Genting Berhad, the holding company. -Beneficiary of a trust which has 13.5% equity interest in Synthetic Genomics Inc., which in turn has 50% interest in SGSI-Asiatic 	Provision of genomic research services by SGSI-Asiatic to ACGT for the period from 1 July 2008 to 31 December 2008	<p>USD7 million</p> <p>or</p> <p>RM22.40 million equivalent*</p>
				Total value of transaction with SGSI-Asiatic	RM22.40 million

* Exchange rate at USD 1 : RM3.2000